Your account is not claimed yet. You can sign up with ORCID to claim your account.

Meis Omran

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Venues

Cancer

Cancers

Hereditary cancer in clinical practice

Karolinska University Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Karolinska University Hospital

Sweden

Resident :: The Department of Oncology

Publications

Meis Omran, Hemming Johansson, Claudia Lundgren, Gustav Silander, Marie Stenmark-Askmalm, Niklas Loman, Annika Baan, Jamila Adra, Ekaterina Kuchinskaya, Lennart Blomqvist, Emma Tham, Svetlana Bajalica-Lagercrantz, Yvonne Brandberg, null null
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study. Cancer 129 (6) (2023)
Meis Omran, Hemming Johansson, Claudia Lundgren, Gustav Silander, Marie Stenmark-Askmalm, Niklas Loman, Annika Baan, Jamila Adra, Ekaterina Kuchinskaya, Lennart Blomqvist, Emma Tham, Svetlana Bajalica-Lagercrantz, Yvonne Brandberg, null null
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study. Cancer 129 (6) (2023)
Meis Omran, Hemming Johansson, Claudia Lundgren, Gustav Silander, Marie Stenmark-Askmalm, Niklas Loman, Annika Baan, Jamila Adra, Ekaterina Kuchinskaya, Lennart Blomqvist, Emma Tham, Svetlana Bajalica-Lagercrantz, Yvonne Brandberg, null null
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study. Cancer (2023)
Meis Omran, Hemming Johansson, Claudia Lundgren, Gustav Silander, Marie Stenmark-Askmalm, Niklas Loman, Annika Baan, Jamila Adra, Ekaterina Kuchinskaya, Lennart Blomqvist, Emma Tham, Svetlana Bajalica-Lagercrantz, Yvonne Brandberg, null null
Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study. Cancer 129 (6) (2023)
Meis Omran, Emma Tham, Yvonne Brandberg, Håkan Ahlström, Claudia Lundgren, Ylva Paulsson-Karlsson, Ekaterina Kuchinskaya, Gustav Silander, Anna Rosén, Fredrik Persson, Henrik Leonhardt, Marie Stenmark-Askmalm, Johanna Berg, Danielle van Westen, Svetlana Bajalica Lagercrantz, Lennart Blomqvist, null null
Whole-Body MRI Surveillance-Baseline Findings in the Swedish Multicentre Hereditary TP53 -Related Cancer Syndrome Study (SWEP53). Cancers 14 (2) (2022)
Meis Omran, Lennart Blomqvist, Yvonne Brandberg, Niklas Pal, Per Kogner, Anne Kinhult Ståhlbom, Emma Tham, Svetlana Bajalica Lagercrantz
Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53. Hereditary cancer in clinical practice 18 (2020)

Meis Omran.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Meis Omran